Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback